iStock likes to keep track of a number of things for our weekly insider buying column. A couple of them come into play this week.
First up, the number of purchase records dramatically fell last week following a month of improving numbers. Maybe, just maybe, investors in corporate boardrooms are weary about Washington D.C. antics and their potential impact on the economy.
The second and more important point, in our view, is the performance history and timing of previous buys from our highlighted shopper.
In the movie business, they call this foreshadowing. You would have made a killing if you did nothing else but ride piggy-back when Repros Therapeutics Inc.'s (RPRX) Ms. Katherine A. Anderson opened the checkbook. She might not be a big buyer, but whoa, it's no doubt that the CPA and Chief Financial Officer, Chief Accounting Officer and Secretary knows how to work the numbers.
Repros Therapeutics is a development stage biopharmaceutical company engaged in the development of new drugs to treat hormonal and reproductive system disorders. Its product portfolio includes Androxal, an oral therapy, which is in Phase III used for the treatment of low testosterone due to secondary hypogonadism; Proellex that is in Phase II used for the treatment of symptoms associated with uterine fibroids and endometriosis; and VASOMAX that is used for the treatment of male erectile dysfunction.
Check out this performance! In April 2012, the numbers cruncher bought 3,000 shares of RPRX at $3.86. She popped out the debit card again in February 2013. That time, the executive bought 1,000 shares at $11.89. She stepped to the plate again on October 10, 2013 at $23.77.
Based on today's price, her first purchase is up more than 500% in the last 18-months, and buy number two has more than doubled in the eight-months. If the third time is the charm or good things really do come in threes, then what's next?
Well, in all likelihood, the biotech company will file for Androxal sometime withi! n the next six-to-nine months. Phase III for Proellex will probably come within a year of Androxal's approval filing with application for Proellex approval in 2016. Meanwhile, VASOMAX® has been on partial clinical hold in the U.S. since 1998, and no further development activities are planned, according to the company's most recent 10-Q.
Overall: Repros Therapeutics Inc.'s (RPRX) is an Adam Dunn stock in our view. They don't have a product to market yet and are at the mercy of the FDA. Like the aforementioned Dunn, RPRX could strike-out or hit a home-run based on the regulatory body's decision; although, Anderson's sterling track-record is hard to ignore.
No comments:
Post a Comment